Milgrom Sarah A, Goodman Karyn A, Nash Garrett M, Paty Philip B, Guillem José G, Temple Larissa K, Weiser Martin R, Garcia-Aguilar Julio
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Ann Surg Oncol. 2014 Jul;21(7):2295-302. doi: 10.1245/s10434-014-3624-7. Epub 2014 Mar 7.
Neoadjuvant radiation therapy (RT) downstages rectal cancer but may increase postoperative morbidity. This study aims to quantify 30-day complication rates after total mesorectal excision (TME) using current techniques and to assess for an association of these complications with neoadjuvant RT.
Stage I-III rectal cancer patients who underwent TME from 2005 to 2010 were identified. Complications occurring within 30 days after TME were retrieved from a prospectively maintained institutional database of postoperative adverse events.
The cohort consisted of 461 patients. Median age was 59 years (range 18-90), and 274 patients (59 %) were male. Comorbid conditions included obesity (n = 147; 32 %), coronary artery disease (n = 83; 18 %), diabetes (n = 65; 14 %), and inflammatory bowel disease (n = 19; 4 %). A low anterior resection (LAR) was performed in 383 cases (83 %), an abdominoperineal resection (APR) was performed in 72 cases (16 %), and a Hartmann's procedure was performed in 6 cases (1 %). Preoperative RT was delivered to 310 patients (67 %; median dose of 50.4 Gy, range 27-55.8 Gy). The 30-day incidence of postoperative mortality was 0.4 % (n = 2), any complication 25 % (n = 117), grade 3 or more complication 5 % (n = 24), intra-abdominal infection 3 % (n = 12), abdominal wound complication 9 % (n = 42), perineal wound complication after APR 11 % (n = 8/72), and anastomotic leak after LAR 2 % (n = 6/383). These events were not associated with neoadjuvant RT.
In a cohort undergoing TME using current techniques, neoadjuvant RT was not associated with 30-day postoperative morbidity or mortality.
新辅助放疗(RT)可使直肠癌降期,但可能增加术后发病率。本研究旨在采用当前技术量化全直肠系膜切除术(TME)后30天的并发症发生率,并评估这些并发症与新辅助放疗之间的相关性。
确定2005年至2010年接受TME的I-III期直肠癌患者。从前瞻性维护的术后不良事件机构数据库中检索TME后30天内发生的并发症。
该队列包括461例患者。中位年龄为59岁(范围18-90岁),274例患者(59%)为男性。合并症包括肥胖(n = 147;32%)、冠状动脉疾病(n = 83;18%)、糖尿病(n = 65;14%)和炎症性肠病(n = 19;4%)。383例(83%)患者行低位前切除术(LAR),72例(16%)患者行腹会阴联合切除术(APR),6例(1%)患者行哈特曼手术。310例患者(67%)接受了术前放疗(中位剂量50.4 Gy,范围27-55.8 Gy)。术后30天死亡率为0.4%(n = 2),任何并发症发生率为25%(n = 117),3级或更高级别并发症发生率为5%(n = 24),腹腔内感染发生率为3%(n = 12),腹部伤口并发症发生率为9%(n = 42),APR后会阴伤口并发症发生率为11%(n = 8/72),LAR后吻合口漏发生率为2%(n = 6/383)。这些事件与新辅助放疗无关。
在采用当前技术进行TME的队列中,新辅助放疗与术后30天的发病率或死亡率无关。